Gastrounit, Medical Section, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Nutr Metab Cardiovasc Dis. 2023 Dec;33(12):2444-2454. doi: 10.1016/j.numecd.2023.07.030. Epub 2023 Jul 28.
Modulation of the gut microbiome composition with probiotics may have beneficial metabolic effects in pregnant women with obesity. The aim was to investigate the effect of probiotic supplementation during pregnancy on metabolic and inflammatory markers and the body composition of the offspring.
A randomized double-blind trial in 50 pregnant women (pre-pregnancy BMI ≥30 and < 35 kg/m) comparing multi-strain probiotics (Vivomixx®; 450 billion CFU/d) versus placebo from 14 to 20 weeks of gestation until delivery was carried out. Participants were followed with two predelivery visits at gestational week 27-30 and 36-37 and with one postdelivery visit. All visits included fasting blood samples (C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), insulin, C-peptide, glucose, glucagon, and glucagon-like peptide-1 (GLP-1)). At delivery, umbilical cord blood samples were collected (GLP-1 and glucagon). At the postdelivery visit, a dual-energy X-ray absorptiometry (DXA) scan of the newborn was performed. Forty-nine of 50 participants completed the study until delivery, and 36 mother-offspring dyads underwent postdelivery examinations including a DXA scan. There were no significant differences in changes in measured biomarkers between the probiotic versus the placebo group. No differences were found in newborn body composition or GLP-1 and glucagon. GLP-1 measured in umbilical blood samples was positively correlated to fat percent in offspring from the probiotic group.
In this study of pregnant women with obesity and their newborns, there was no effect of probiotic supplementation in mothers or babies on metabolic or inflammatory biomarkers or on body composition of offspring. This study was registered at clinicaltrials.gov as NCT02508844.
益生菌调节肠道微生物组成可能对肥胖孕妇有有益的代谢作用。本研究旨在探讨孕期补充益生菌对代谢和炎症标志物以及后代身体成分的影响。
对 50 名孕妇（孕前 BMI≥30 且＜35kg/m）进行了一项随机双盲试验，比较了从 14 周至 20 周妊娠至分娩时多菌株益生菌（Vivomixx®；4500 亿 CFU/d）与安慰剂的效果。参与者在妊娠 27-30 周和 36-37 周进行了两次产前访视，并在产后进行了一次访视。所有访视均包括空腹血样（C 反应蛋白（CRP）、丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、胰岛素、C 肽、血糖、胰高血糖素和胰高血糖素样肽-1（GLP-1））。分娩时采集脐血样（GLP-1 和胰高血糖素）。产后访视时，对新生儿进行双能 X 射线吸收法（DXA）扫描。50 名参与者中有 49 名完成了分娩前的研究，36 对母婴对接受了产后检查，包括 DXA 扫描。益生菌组与安慰剂组之间，测量生物标志物的变化无显著差异。新生儿身体成分或 GLP-1 和胰高血糖素无差异。来自益生菌组的脐血样中 GLP-1 与后代的脂肪百分比呈正相关。
在这项针对肥胖孕妇及其新生儿的研究中，母亲或婴儿补充益生菌对代谢或炎症标志物或后代身体成分均无影响。本研究在 clinicaltrials.gov 注册，编号为 NCT02508844。
